OR WAIT null SECS
Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.
The use of approved platform technologies can reduce the time and cost required to generate new vaccines.
Established vaccine manufacturing technologies are complex, often highly customized, and typically require dedicated facilities. Development and approval times can be lengthy, presenting hurdles for medical professionals seeking rapid response to pandemic diseases.
Standardized vaccine manufacturing platforms that can be deployed across different vaccines and vaccine types, could speed the delivery of vaccines and enable manufacturing in emerging economies. Technical and funding challenges must be overcome to bring the advanced manufacturing potential to reality.
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
When referring to this article, please cite it as C Challener, " Accelerating Vaccine Development and Manufacturing," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).